Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 3 to Not applicable
    • Trial status: Recruiting to Completed
    • Primary and study completion dates changed from estimate of Dec 2013 to Feb 2008
    • Site details revised
    v9
  2. Primary completion date: Dec 2012 to Dec 2013
    • Study arms: 0 to 1
    v8
  3. Re-verified, no change to tracked fieldsv7
  4. Primary completion date: Dec 2011 to Dec 2012
    • Study completion date: Dec 2011 to Dec 2013
    v6
  5. Site contact updatedv5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary and study completion dates: Dec 2008 to Dec 2011v4
  2. Primary completion date: Dec 2008
    • Study completion date: Jul 2008 to Dec 2008
    • Site contact updated
    v3
  3. Secondary endpoints: 3 to 1
    • Site contact updated
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Brachytherapy, or Transperineal implantation of the prostate (TPIP), is a recognized form of treatment for localized cancer of the prostate. TPIP has been used at the British Columbia Cancer Agency (BCCA) since 1998. As part of the treatment, some patients also require hormone therapy for 6 months. This is given as injections of a drug called an LHRH agonist. The LHRH agonist is made either as short-acting (1-month) or long-acting (3 month) injections. The LHRH agonist lowers testosterone levels, which helps make delivery of TPIP easier, and more effective. There are specific guidelines regarding the use of LHRH agonist treatment with brachytherapy, however there is no policy whether short-acting or long-acting LHRH agonists should be used. Analysis of results from BC has shown that there seems to be a delay in the time in which testosterone levels return to normal in men who receive the long-acting LHRH agonist compared with the short-acting LHRH agonist, however this is not known for sure.
Trial Details
NCT Number NCT00175383
Lead Sponsor University of British Columbia
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov